Jianguo Qiu1,2, Shuting Chen1, Hong Wu1. 1. The First Affiliated Hospital of Chongqing Medical University, Chongqing, China. 2. Department of Hepatobiliary Pancreatic Surgery, West China Hospital, Sichuan University, Chengdu, China.
Abstract
OBJECTIVES: Surgical resection represents the main curative treatment for giant hepatic haemangioma (GHH). The aim of this study was to compare the respective outcomes of hepatic enucleation (HE) and hepatic resection (HR) for GHH. METHODS: Giant hepatic haemangioma was defined as haemangioma of 5-15 cm in size. A prospectively maintained database consisting of a series of consecutive patients who underwent HE or HR of GHH from January 2004 to December 2013 was analysed. RESULTS: Hepatic enucleation was performed in 386 (52.9%) patients and HR in 344 (47.1%) of a final cohort of 730 patients. The median size of GHH was similar in the HR and HE groups (9.8 and 10.6 cm, respectively; P = 0.752). The HE group had a shorter median operative time (150 min versus 240 min; P = 0.034), shorter median hospital stay (5.7 days versus 8.6 days; P < 0.001), lower median blood loss (400 ml versus 860 ml; P < 0.001), and fewer complications (17.6% versus 28.2%; P < 0.001) than the HR group. Quality of life scores in both the HR and HE groups significantly improved compared with preoperative levels and were similar to those found in healthy Chinese individuals following surgery, confirming the efficacy of both treatments. CONCLUSIONS: Hepatic enucleation was associated with favourable operative outcomes compared with HR and is a safe and effective alternative to partial hepatectomy for GHH.
OBJECTIVES: Surgical resection represents the main curative treatment for giant hepatic haemangioma (GHH). The aim of this study was to compare the respective outcomes of hepatic enucleation (HE) and hepatic resection (HR) for GHH. METHODS:Giant hepatic haemangioma was defined as haemangioma of 5-15 cm in size. A prospectively maintained database consisting of a series of consecutive patients who underwent HE or HR of GHH from January 2004 to December 2013 was analysed. RESULTS: Hepatic enucleation was performed in 386 (52.9%) patients and HR in 344 (47.1%) of a final cohort of 730 patients. The median size of GHH was similar in the HR and HE groups (9.8 and 10.6 cm, respectively; P = 0.752). The HE group had a shorter median operative time (150 min versus 240 min; P = 0.034), shorter median hospital stay (5.7 days versus 8.6 days; P < 0.001), lower median blood loss (400 ml versus 860 ml; P < 0.001), and fewer complications (17.6% versus 28.2%; P < 0.001) than the HR group. Quality of life scores in both the HR and HE groups significantly improved compared with preoperative levels and were similar to those found in healthy Chinese individuals following surgery, confirming the efficacy of both treatments. CONCLUSIONS: Hepatic enucleation was associated with favourable operative outcomes compared with HR and is a safe and effective alternative to partial hepatectomy for GHH.
Authors: Thomas Schnelldorfer; Adam L Ware; Rory Smoot; Cathy D Schleck; William S Harmsen; David M Nagorney Journal: J Am Coll Surg Date: 2010-10-25 Impact factor: 6.113
Authors: J Yamamoto; T Kosuge; T Takayama; K Shimada; S Yamasaki; H Ozaki; N Yamaguchi; S Mizuno; M Makuuchi Journal: Surgery Date: 1994-03 Impact factor: 3.982
Authors: Parsia A Vagefi; Ingo Klein; Bruce Gelb; Bilal Hameed; Stephen L Moff; Jeff P Simko; Oren K Fix; Helge Eilers; John R Feiner; Nancy L Ascher; Chris E Freise; Nathan M Bass Journal: J Gastrointest Surg Date: 2010-06-12 Impact factor: 3.452
Authors: Renée Duijzer; Thijs R M Barten; Christian B Staring; Joost P H Drenth; Tom J G Gevers Journal: J Clin Gastroenterol Date: 2022-08-19 Impact factor: 3.174